New Age Alpha Advisors LLC Invests $8.55 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

New Age Alpha Advisors LLC acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 70,340 shares of the biotechnology company’s stock, valued at approximately $8,553,000.

A number of other large investors also recently bought and sold shares of the business. Louisiana State Employees Retirement System raised its holdings in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after purchasing an additional 100 shares in the last quarter. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. grew its holdings in Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 138 shares during the last quarter. CIBC Asset Management Inc increased its position in shares of Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 139 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 145 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reissued a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft reduced their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Finally, Royal Bank of Canada cut their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $167.41.

Sarepta Therapeutics Trading Down 1.5 %

Shares of SRPT stock opened at $71.81 on Friday. The firm’s 50 day moving average price is $103.61 and its two-hundred day moving average price is $116.46. Sarepta Therapeutics, Inc. has a fifty-two week low of $70.91 and a fifty-two week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of 57.45 and a beta of 0.79.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.